Pets at Home’s vet arm underpins value as retail division lags: Jefferies

Pets at Home issued a profit warning, significantly revising its fiscal 2026 profit before tax guidance to £95 million from £185 million, driven by a severe underperformance in its retail division, which saw a 5% year-to-date sales decline and market share losses. Jefferies subsequently reduced its group PBT forecasts by 18% to £94 million for fiscal 2026, but noted that the robust veterinary business, now accounting for approximately 90% of group PBT, underpins the company's market value, maintaining a base case price target of 250p despite the retail segment's struggles.

Analysis

Pets at Home has issued a severe profit warning, revising its fiscal 2026 profit before tax (PBT) guidance downward from approximately £185 million to a £95 million midpoint. This revision is attributed entirely to a significant deterioration in its retail division, where PBT is now forecast to decline from £101 million in fiscal 2022 to just £31 million by fiscal 2026. The retail segment's challenges are multifaceted, evidenced by a 5% year-to-date sales decline, underperformance in high-margin accessory and nutrition categories, and a loss of market share after years of gains. The recent departure of CEO Lyssa McGowan underscores the severity of these operational issues, which management reportedly diagnoses as a product and range problem rather than a pricing issue. In stark contrast, the company's veterinary business remains robust, now constituting approximately 90% of the group's projected PBT. According to Jefferies' sum-of-the-parts valuation, the veterinary division's performance underpins the entire market capitalization, providing a valuation floor despite the retail headwinds. Jefferies has consequently cut its group PBT forecast by 18% to £94 million for fiscal 2026 and established a base case price target of 250p, which assigns a low 6x P/E multiple to the retail unit while valuing the veterinary business on a discounted cash flow basis.

Key Decisions for Investors

• Investors should evaluate Pets at Home using a sum-of-the-parts framework, heavily discounting the struggling retail division while focusing on the valuation of the resilient veterinary business, which analysts estimate accounts for the entire market capitalization.
• Closely monitor the performance and free cash flow generation of the veterinary segment, as its continued stability is the primary thesis supporting the stock's current valuation floor.
• Given the recent CEO departure and market share losses, any investment thesis must account for significant execution risk in the retail turnaround plan, treating potential recovery as an upside catalyst rather than a base expectation.
• Consider the range of valuation scenarios, from the 150p downside case where retail is valued at zero to the 320p upside case contingent on a successful retail recovery, to define entry points and risk tolerance.